

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/560,514	05/30/2006	Adrian Hill	ISI-100	6383
	7590 07/02/200 IK LLOYD & SALIW	•	EXAMINER	
	NAL ASSOCIATION	SNYDER, STUART		
	PO BOX 142950 GAINESVILLE, FL 32614-2950		ART UNIT	PAPER NUMBER
			1648	
			MAIL DATE	DELIVERY MODE
			07/02/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		Application No.	Applicant(s)			
•		10/560,514	HILL ET AL.			
Office Action Summary		Examiner	Art Unit			
•		Stuart W. Snyder	1648			
The MAILING DATE of this	communication app	ears on the cover sheet with the c				
Period for Reply						
after SIX (6) MONTHS from the mailing date If NO period for reply is specified above, the Failure to reply within the set or extended be	M THE MAILING DA he provisions of 37 CFR 1.13 h of this communication. maximum statutory period we period for reply will, by statute, here months after the mailing	IS SET TO EXPIRE 1 MONTH(ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim will apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE date of this communication, even if timely filed	N. the mailing date of this communication. D (35 U.S.C. § 133).			
Status						
1) Responsive to communica	tion(s) filed on <u>13 De</u>	ecember 200 <u>5</u> .				
2a) ☐ This action is FINAL .	2b)⊠ This	action is non-final.	•			
•—	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4)	is/are withdrav ved. cted. cted to.	vn from consideration.				
Application Papers						
9) The specification is objecte						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s) 1) Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawir 3) Information Disclosure Statement(s) (F	ng Review (PTO-948)	4) Interview Summary Paper No(s)/Mail D 5) Notice of Informal I	ate			
Information Disclosure Statement(s) (F Paper No(s)/Mail Date	10/36/00)	6) Other:				

Application/Control Number: 10/560,514

Art Unit: 1648

DETAILED ACTION

Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 58-64, drawn to a composition useful in eliciting an immune response.

Group II, claim(s) 65-75, drawn to a method of eliciting an immune response.

The inventions listed as Groups I and II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The common technical feature of the claimed invention is the use of replication incompetent virus (viral capsid incapable of replication) and an additional immunogenic adjuvant to induce B-cell and T-cell immune responses. Chevalier, et al. teaches such compositions and methods of use.

2. This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1. The species are as follows:

Application/Control Number: 10/560,514

Art Unit: 1648

fowlpox virus

Genus II—antigen: M. tuberculosis, Plasmodium sp., influenza virus, HIV,

Genus I—capsid: Poxvirus, adenovirus, MVA, NYVAC, Orthopox virus,

HBV, HCV, CMV, HPV, bacteria, leshmania, or tumor antigens.

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

The claims are deemed to correspond to the species listed above in the following manner:

All species are defined in claim 64.

The following claim(s) are generic: All claims are generic.

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons:

Application/Control Number: 10/560,514

Art Unit: 1648

The common technical feature of the claimed invention is the use of replication incompetent virus (viral capsid incapable of replication) and an additional immunogenic adjuvant to induce B-cell and T-cell immune responses. Chevalier, et al. teaches such compositions and methods of use.

3. Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

4. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at

Page 5

Application/Control Number: 10/560,514

Art Unit: 1648

least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Stuart W. Snyder whose telephone number is (571) 272-9945. The examiner can normally be reached on 9:00 AM-5:30 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce R. Campell can be reached on (571) 272-0974. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Stuart W Snyder Examiner Art Unit 1648

BRUCE R. CAMPELL, PH.D SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600